Compare BLDP & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | ALVO |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | Canada | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2009 | N/A |
| Metric | BLDP | ALVO |
|---|---|---|
| Price | $3.51 | $3.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $2.34 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 7.5M | 1.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.53 | $13.28 |
| Revenue Next Year | $18.02 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $2.94 |
| 52 Week High | $6.57 | $9.94 |
| Indicator | BLDP | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 46.87 |
| Support Level | $2.55 | $3.55 |
| Resistance Level | $3.71 | $3.83 |
| Average True Range (ATR) | 0.36 | 0.23 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 1.33 | 14.00 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from United States followed by Poland, Canada, and other countries.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.